Clinical Trials Directory

Trials / Terminated

TerminatedNCT03914495

The Role of Microbiome Reprogramming on Liver Fat Accumulation

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
57 (actual)
Sponsor
AdventHealth Translational Research Institute · Academic / Other
Sex
All
Age
35 Years – 65 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTInulinPowdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
DIETARY_SUPPLEMENTPlaceboPowdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.

Timeline

Start date
2019-05-21
Primary completion
2021-06-02
Completion
2021-06-09
First posted
2019-04-16
Last updated
2023-02-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03914495. Inclusion in this directory is not an endorsement.